Absolutely, agree with you. Nothing wrong with company, it's management and the product (Vascepa) itself. I believe, Management is doing a decent job so far. Disclosure, I am long this stock and still believe this company will be acquired sooner or later. But these analysts, I think jumped guns and made such bad calls last year. I would say, only Akiva Felt (Wedbush) made a reasonable call,at the right time. All the other analysts (price targets , Ritu Baral - $28, Aegis Capital - $35, JPM $19, Citi - $21, Leerink Swann -$26, MKM Partners $22 and a bunch of other analysts had price targets above $20). Lesson learned the hard way - When every analyst on WallStreet is bullish a certain stock, you absolutely gotta stay away from that stock. I have seen this time and again. I don't believe there was one analyst who was bearish AMRN around June-October 2012.
It was a high risk/reward investment at that time. If Vascepa had received NCE decision last year (before November) , we probably would not be talking about this now. It just a bad luck for AMRN investors who were hoping for a quick buyout.